Cover Image
市場調查報告書

纖維母細胞生長因子2:開發中產品分析

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 364846
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
纖維母細胞生長因子2:開發中產品分析 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 64 Pages
簡介

本報告提供以纖維母細胞生長因子2為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

纖維母細胞生長因子2概要

治療藥的開發

纖維母細胞生長因子2:開發中的產品 - 各開發階段

纖維母細胞生長因子2:開發中的產品 - 各治療範圍

纖維母細胞生長因子2:開發中的產品 - 各適應症

纖維母細胞生長因子2:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

纖維母細胞生長因子2:企業開發中的產品

纖維母細胞生長因子2:大學/機關開發中的產品

纖維母細胞生長因子2:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

纖維母細胞生長因子2治療藥的開發企業

  • F. Hoffmann-La Roche Ltd.
  • Kringle Pharma, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Ohr Pharmaceutical Inc.
  • Progen Pharmaceuticals Limited
  • Ribomic Inc.

藥物簡介

纖維母細胞生長因子2:暫停中的計劃

纖維母細胞生長因子2:開發中止的產品

纖維母細胞生長因子2:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0641TDB

Summary

Global Markets Direct's, 'Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016', provides in depth analysis on Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
  • The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Overview 7
  • Therapeutics Development 8
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Stage of Development 8
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Therapy Area 9
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Indication 10
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Products Glance 12
  • Late Stage Products 12
  • Early Stage Products 13
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Companies 14
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Universities/Institutes 16
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment 18
  • Assessment by Monotherapy/Combination Products 18
  • Assessment by Mechanism of Action 19
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development 25
  • ID Pharma Co., Ltd. 25
  • Kringle Pharma, Inc. 26
  • Momenta Pharmaceuticals, Inc. 27
  • Ohr Pharmaceutical Inc. 28
  • Ribomic Inc. 29
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles 30
  • Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • CT-400 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • CT-400P - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • DVC-10101 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • necuparanib - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • NK-4 - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • Protein to Activate FGF2 for Wound Healing - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • RBM-007 - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • Recombinant Protein to Inhibit FGF-2 for Cancer - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • squalamine lactate - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • TR-764 - Drug Profile 48
  • Product Description 48
  • Mechanism Of Action 48
  • R&D Progress 48
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Projects 49
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products 51
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Featured News & Press Releases 52
  • Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis 52
  • Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO 52
  • May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting 53
  • May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee 54
  • Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA 54
  • Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program 55
  • Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program 55
  • Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 56
  • Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting 57
  • Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 58
  • Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology 58
  • Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 59
  • Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 60
  • May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 61
  • May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference 61
  • Appendix 63
  • Methodology 63
  • Coverage 63
  • Secondary Research 63
  • Primary Research 63
  • Expert Panel Validation 63
  • Contact Us 63
  • Disclaimer 64

List of Tables

  • Number of Products under Development for, H2 2016 8
  • Number of Products under Development by Therapy Area, H2 2016 9
  • Number of Products under Development by Indication, H2 2016 11
  • Comparative Analysis by Late Stage Development, H2 2016 12
  • Comparative Analysis by Early Stage Products, H2 2016 13
  • Number of Products under Development by Companies, H2 2016 14
  • Products under Development by Companies, H2 2016 15
  • Number of Products under Investigation by Universities/Institutes, H2 2016 16
  • Products under Investigation by Universities/Institutes, H2 2016 17
  • Assessment by Monotherapy/Combination Products, H2 2016 18
  • Number of Products by Stage and Mechanism of Action, H2 2016 20
  • Number of Products by Stage and Route of Administration, H2 2016 22
  • Number of Products by Stage and Molecule Type, H2 2016 24
  • Pipeline by ID Pharma Co., Ltd., H2 2016 25
  • Pipeline by Kringle Pharma, Inc., H2 2016 26
  • Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 27
  • Pipeline by Ohr Pharmaceutical Inc., H2 2016 28
  • Pipeline by Ribomic Inc., H2 2016 29
  • Dormant Projects, H2 2016 49
  • Dormant Projects (Contd..1), H2 2016 50
  • Discontinued Products, H2 2016 51

List of Figures

  • Number of Products under Development for, H2 2016 8
  • Number of Products under Development by Therapy Area, H2 2016 9
  • Number of Products under Development by Top 10 Indication, H2 2016 10
  • Comparative Analysis by Late Stage Development, H2 2016 12
  • Comparative Analysis by Early Stage Products, H2 2016 13
  • Assessment by Monotherapy/Combination Products, H2 2016 18
  • Number of Products by Mechanism of Actions, H2 2016 19
  • Number of Products by Stage and Mechanism of Actions, H2 2016 19
  • Number of Products by Routes of Administration, H2 2016 21
  • Number of Products by Stage and Routes of Administration, H2 2016 21
  • Number of Products by Molecule Types, H2 2016 23
  • Number of Products by Stage and Molecule Type, H2 2016 23
Back to Top